Takeda signs US$600M AI drug discovery deal with Insilico

Takeda has entered a strategic collaboration with Hong Kong-based Insilico Medicine to use AI in early-stage drug discovery across the Japanese pharmaceutical company’s therapeutic areas.

The companies did not disclose which therapeutic areas or disease targets will be covered under the collaboration. The agreement gives Takeda access to Insilico’s Pharma.AI platform, which supports biological target identification, molecular design, and clinical trial prediction.

The companies said the collaboration will focus on identifying drug candidates that meet predefined scientific and early development criteria. Insilico will lead the AI-driven discovery work, while Takeda will take responsibility for advancing selected candidates through clinical development.

Deal value and development rights

Takeda will receive exclusive worldwide rights to develop, manufacture, and commercialise novel therapeutics selected through the collaboration.

Insilico said the deal includes about US$60 million in project initiation fees, near-term payments, and milestones. The total value could reach...